BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $247,710,566 | -17.4% | 6,563,608 | -0.3% | 1.30% | -10.2% |
Q2 2023 | $299,844,849 | +11.1% | 6,581,318 | -1.1% | 1.45% | +1.0% |
Q1 2023 | $269,827,347 | -51.3% | 6,652,548 | -38.8% | 1.44% | -55.1% |
Q4 2022 | $553,844,048 | -13.4% | 10,866,079 | -8.5% | 3.20% | -15.8% |
Q3 2022 | $639,644,000 | -23.5% | 11,876,040 | -8.8% | 3.80% | -16.7% |
Q2 2022 | $836,163,000 | -34.3% | 13,018,264 | -20.6% | 4.56% | -21.8% |
Q1 2022 | $1,271,794,000 | -30.0% | 16,401,780 | -22.5% | 5.82% | -22.0% |
Q4 2021 | $1,817,350,000 | +9.0% | 21,171,371 | +2.1% | 7.47% | +7.7% |
Q3 2021 | $1,667,946,000 | -1.4% | 20,737,864 | -1.3% | 6.93% | -1.1% |
Q2 2021 | $1,690,992,000 | -4.4% | 21,006,109 | +0.1% | 7.01% | -5.5% |
Q1 2021 | $1,769,716,000 | +26.6% | 20,983,112 | +20.4% | 7.42% | +18.9% |
Q4 2020 | $1,398,147,000 | +46.6% | 17,424,560 | +46.9% | 6.24% | +23.3% |
Q3 2020 | $953,613,000 | +4.4% | 11,857,911 | +11.8% | 5.06% | -3.9% |
Q2 2020 | $913,185,000 | +10.7% | 10,606,094 | +4.4% | 5.27% | -10.0% |
Q1 2020 | $824,943,000 | +44.7% | 10,160,652 | +49.0% | 5.86% | +60.6% |
Q4 2019 | $570,105,000 | – | 6,817,806 | – | 3.65% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |